It is not clear whether this vaccine will provide immunity for 5 to 10 years like other vaccines, or whether it will provide lifelong immunity. If it is effective, the laboratory conditions it needs are different from the standard clinical antibody test we do, because it needs a live virus and a P3 laboratory to detect the neutralizing antibody produced after your vaccination.
In the process of clinical trial evaluation and approval by the Food and Drug Administration, we have a data that after the vaccine is marketed and used in the general population, it can produce more than 90% neutralizing antibodies. It is generally not recommended to do this antibody test routinely. The antibody produced after inoculation with coronavirus pneumonia-19 vaccine can be maintained for more than 6 months, and the level can be maintained at a high level after 6 months, reaching the standards of the World Health Organization. However, the specific length of time varies from person to person. Some times may be longer. In any case, the coronavirus pneumonia-19 vaccine can effectively prevent novel coronavirus infection, reduce the risk of infection, and play a preventive role to some extent. It is recommended that 18 to 59-year-old people be vaccinated in good health.
People with diseases should not be vaccinated, such as cancer patients, people with low immunity, diabetic patients, pregnant women and other people should not be vaccinated for the time being. Prevent bad consequences. Inoculators also need to observe and go to the hospital or inoculation point in time if they feel unwell. These available data show that the recurrence rate of coronavirus pneumonia-19 within 6 months after Novozymes coronavirus infection is very low. But this does not mean that after six months, he will definitely not be protected, just that we no longer have observation data. So for the time being, we suggest that he can get another shot if necessary, which is also an internationally recognized suggestion.